| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10958054 | Neurochemistry International | 2012 | 10 Pages |
Abstract
⺠NGF antagonism is the first novel class of pain therapeutic in the last 30 years. ⺠The structural biology of NGF, p75NTR, and TrkA are reviewed in the context pharmacological target development. ⺠This article highlights the current state of therapeutic strategies for the targeting of NGF antagonists. ⺠The review provides a resource to summarize our current understanding of neurotrophin/receptor related structural biology. ⺠The review provides a comprehensive resource to summarize all reported NGF antagonists.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Joseph K. Eibl, Bridget C. Strasser, Gregory M. Ross,